Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)
Status:
Completed
Trial end date:
2017-06-18
Target enrollment:
Participant gender:
Summary
Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by
Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like
hypotensive therapy in subjects with primary open angle glaucoma or ocular hypertension.
Study design: a multicentric, prospective, crossover (2x2), double blind clinical study.
Sample size: one hundred patients with primary open angle glaucoma or ocular hypertension.
Patients in the period 1: In the first sequence 30 patients will be assigned to receive the
ophthalmic solution: Krytantek Ofteno ® (timolol 0.5%%/brimonidine 0.2%/dorzolamide 2%) 1
drop B.I.D. during 30 days and the second sequence 30 patients will be assigned to receive
the ophthalmic solution: PRO-122 1 drop B.I.D. during 30 days in the same period. Washout
period: 20 hours. Patients in the period 2: the pharmacological intervention change to the
opposite therapy for 30 days